APIM Therapeutics completes private placement and enters phase-2
APIM Therapeutics today announces the completion of a private placement directed towards existing and certain new investors in the Company. The procee…
APIM Therapeutics announces IND for ATX-101 in Ovarian Cancer
APIM Therapeutics AS announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application (IND) for a Phas…
APIM Therapeutics AS announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application (IND) for a Phas…
The Norwegian Investment Company Saga Pure ASA has entered into an agreement to invest NOK 75 mill into Sarsia Seed portfolio company Heimdall Power A…